엘앤씨바이오

290650KOSDAQ의약품 제조업

62.5 / 100

Reference Date: 2026-06-10

Financial Score16.5 / 40

News Sentiment20.0 / 25

Momentum16.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 28.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

L&N Bio is a specialist in regenerative medicine, developing and selling human tissue implants and medical devices, along with cosmetic and pharmaceutical businesses. Its flagship product, Acellular Dermal Matrix (MegaDerm), is used for breast reconstruction after cancer treatment, and the company expands its global market by exporting tissue-based medical devices. It aims to grow into a comprehensive healthcare platform through R&D in regenerative medicine.

Number of Employees

155people

Average Salary

49.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

10.02Industry Average 0.890.0Point

11.3x industry avg (risky)

ROE

-55.32Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

4.94Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.6% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲3.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 14.6% (declining, 3yr)

Detailed News Sentiment

13 totalPositive 9Neutral 1Negative 3Average Sentiment Score 80

Positive
코스피, 8000선 탈환…‘검은 월요일’ 딛고 7% 급등
코스피의 급등으로 엘앤씨바이오 포함 주요 기업들의 주가가 상승하며 시장 회복을 이끌었다.
Negative
코스피 8000선 턱걸이…반도체 쇼크에 증시 패닉(종합)
엘앤씨바이오를 포함한 코스피 지수가 반도체 기업 브로드컴 실적 악화로 인해 급락하며 부정적 영향을 받고 있다.
Negative
반도체주 ‘휘청’ 코스피, 6% 급락 8,000대…매도 사이드카 발동
엘앤씨바이오를 포함한 코스피 지수가 외국인 매도 지속으로 인해 6% 이상 급락하며 시장 불안이 고조되었다.

Detailed Momentum

52-week position5.0Point

52w mid range (55%)

Current 77,500Won52-week high 118,30052-week low 26,800

1-month return6.0Point

1m +28.31% (strong rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral주식등의대량보유상황보고서(약식)2026-06-05
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-05-29
Neutral분기보고서 (2026.03)2026-05-15